News Search Results
Apr 07, 2025, 10:30 ET US Single-Cell Analysis Market worth US$2,695.3 million by 2029 with 14.3% CAGR | MarketsandMarkets™
segment growth. By Based on end user, the US single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers. The academic & research laboratories
More news about: MarketsandMarkets
Apr 07, 2025, 10:15 ET United States (USA) Testing, Inspection and Certification (TIC) Market worth $55.66 billion by 2030 - Exclusive Report by MarketsandMarkets™
pressure and patient safety and product effectiveness concerns. The development of medical technologies such as medical devices, pharmaceuticals, biotechnology products, and diagnostic tools has increased the need for more stringent testing and certification processes. Furthermore, the increased incidence
More news about: MarketsandMarkets
Apr 07, 2025, 09:29 ET European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Apr 07, 2025, 09:28 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
Apr 07, 2025, 09:00 ET Pivot Bio Announces Appointment of Travis Frey as Chief Technology Officer
in plant breeding and plant genetics from the University of Wisconsin-Madison. He holds a Ph.D. in plant biology and biotechnology from the University of Delaware and Dupont/Pioneer. In addition, in 2018, Frey completed an MBA at the University
More news about: Pivot Bio, Inc
Apr 07, 2025, 08:30 ET Mission BioCapital Announces 2024 Platinum Ticket Investments and Opening of $4 Million 2025 Platinum Program Contest
will be required for application. "Developing a biotechnology discovery into a commercial product is a complex process. We are excited to join the Mission BioCapital Platinum Program sponsorship consortium to help worthwhile biotechnology start-ups access foundational technologies that enable
More news about: Mission BioCapital
Apr 07, 2025, 08:30 ET Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Incorporated at (877) 750-8310 (toll-free) or (212) 750-5833. About Aerovate Therapeutics, Inc. Aerovate Therapeutics is a biotechnology company that was focused on improving the lives of patients with rare cardiopulmonary disease. For more information, please visit www.aerovatetx.com.
More news about: Aerovate Therapeutics
Apr 07, 2025, 08:24 ET TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
cancer." Prior to joining TuHURA, Dr. Le Bourdonnec served as the Chief Scientific Officer and Scientific Advisor for HDAX Therapeutics, a biotechnology company pioneering a novel approach to targeting HDAC6 for the discovery and development of breakthrough therapeutics for high unmet medical needs.
More news about: TuHURA Biosciences, Inc.
Apr 07, 2025, 05:45 ET Shareholders of Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
Apr 07, 2025, 05:45 ET Class Action Filed Against ICON Public Limited Company (ICLR) Seeking Recovery for Investors - Contact The Gross Law Firm
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Apr 05, 2025, 18:30 ET Breakthrough Prize Foundation Announces Student Winner of 10th Annual Breakthrough Junior Challenge Science Video Competition
idea in a really smart, original and funny way." Jasmine's winning entry explains mechanogenetic cellular engineering, an innovative biotechnology, exploring how it works and its potential as a medical tool in the future. The short film can be seen
More news about: The Breakthrough Prize
Apr 04, 2025, 16:05 ET Spyre Therapeutics Announces Grants of Inducement Awards
April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience
More news about: Spyre Therapeutics, Inc.
Apr 04, 2025, 16:05 ET China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about
More news about: China Pharma Holdings, Inc.
Apr 04, 2025, 12:00 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Apr 04, 2025, 09:30 ET SkylineDx Presents Landmark Study on Merlin CP-GEP beyond SLNB prediction: Transforming Melanoma Risk Assessment
diagnostic service providers globally to bring this test to market and increase patient access. About SkylineDx SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
Apr 04, 2025, 09:10 ET NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
April 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced that two members of its Scientific Advisory Board
More news about: NeuroSense
Apr 04, 2025, 09:00 ET Reishi™ Enters a New Era of Interior Design with Its First Industrial Collaboration with Ligne Roset
MycoWorksIn 2013, artists Philip Ross and Sophia Wang founded MycoWorks, a biotechnology dedicated to growing the future of materials. MycoWorks' patented Fine Mycelium™ platform engineers mycelium as it grows, crafting biomaterials
More news about: MycoWorks
Apr 04, 2025, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
employees vesting over four years with a one-year cliff. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Apr 04, 2025, 08:00 ET Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
pharmaceutical companies and small biotechnology firms – and was instrumental in the development of several first-in-class and best-in-class approved medicines. Before joining Neurocrine, he was the President and Chief Executive Officer of ImmunoBrain, a clinical-stage biotechnology firm focused on developing
More news about: Neurocrine Biosciences, Inc.
Apr 04, 2025, 05:45 ET Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)
April 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 04, 2025, 05:45 ET ICON Public Limited Company Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 11, 2025 to Discuss Your Rights - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Apr 04, 2025, 03:42 ET AIM Congress 2025 Kicks Off in Abu Dhabi on Monday with 20,000 Participants
cover diverse sectors, including intelligent agriculture, energy, infrastructure, finance and capital markets, ICT, manufacturing, medical tourism, biotechnology, medical technology, pharmaceuticals, international trade, logistics and transportation, water technology, tourism and education. Roundtable
More news about: AIM Congress
Apr 04, 2025, 03:34 ET AIM Congress 2025 Kicks Off in Abu Dhabi on Monday with 20,000 Participants
cover diverse sectors, including intelligent agriculture, energy, infrastructure, finance and capital markets, ICT, manufacturing, medical tourism, biotechnology, medical technology, pharmaceuticals, international trade, logistics and transportation, water technology, tourism and education. Roundtable
More news about: AIM Congress
Apr 03, 2025, 19:14 ET 35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN
life-changing value. As a Japan-based global specialty pharmaceutical company, we have invested in drug discovery and biotechnology innovation for more than 70 years. We are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential
More news about: La Jolla Institute for Immunology
Apr 03, 2025, 18:35 ET ICLR Deadline: ICLR Purchasers with Losses in Excess of $100K Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.